Efficacy of immunization against hepatitis B virus infection in children with cancer

Simple item page
dc.contributor.buuauthorMeral, Adalet
dc.contributor.buuauthorSevinir, Betül
dc.contributor.buuauthorGünay, Ünsal
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Çocuk Hematoloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Pediatrik Onkoloji Anabilim Dalı.tr_TR
dc.contributor.researcheridAAH-1570-2021tr_TR
dc.date.accessioned2021-07-02T13:38:06Z
dc.date.available2021-07-02T13:38:06Z
dc.date.issued2000
dc.description.abstractBackground. The purpose of this study was to evaluate the impact of hepatitis B prophylaxis in preventing hepatitis B infection in children with malignancy. Procedure, Between May, 1993, and September, 1998, a total of 151 children (95 boys, 56 girls), 29 (19%) with lymphoma, 58 (39%) with leukemia, and 64 (42%) with solid tumor, were screened for hepatitis B Virus (HBV). The mean age was 7.5 +/- 2.5 years. Children with negative serology; received active and/or passive immunization. HBsAg and anti-HBs were positive prior to vaccination in 16 (10%) and 17 (11%) children, respectively. One hundred eighteen children (78%) of one hundred fifty-one with negative serology were included in the vaccination program. The vaccine dose was 40 mu g. Children With solid tumor and lymphoma received recombinant hepatitis B vaccine at diagnosis, repeated at months 1, 2, and 12. Hyperimmunglobulin was administered monthly in children with leukemia during the intensive chemotherapy period. They were then vaccinated following the third month of maintenance therapy with the schedule described above. Anti-HBs titers were measured every 3 months, and titers above 10 mlU/ml were accepted as protective. Results. Anti-HBs positivity after the first three doses was 77% in solid tumors, 88% in acute leukemia, and 48% in lymphomas. Anti-HBs positivity with respect to diagnosis in children completing the vaccination schedule was 94% in solid tumor, 90% in leukemia, and 74% in lymphoma (P > 0.05). Thirty-three percent of children have not received the fourth dose as yet. In total 78% of the children developed protective antibody titers with or without the fourth dose, and none was infected with HBV during 3 years of follow-up. Ten (39%) of twenty-six children who remained unresponsive to immunization were infected with HBV. Conclusions. These data reveal that HBV prophylaxis is necessary and that our vaccination schedule is effective in preventing HBV infection in these children.en_US
dc.identifier.citationMeral, A. vd. (2000). "Efficacy of immunization against hepatitis B virus infection in children with cancer". Medical and Pediatric Oncology, 35(1), 47-51.en_US
dc.identifier.endpage51tr_TR
dc.identifier.issn0098-1532
dc.identifier.issue1tr_TR
dc.identifier.pubmed10881007tr_TR
dc.identifier.scopus2-s2.0-0033949885tr_TR
dc.identifier.startpage47tr_TR
dc.identifier.urihttps://doi.org/10.1002/1096-911X(200007)35:1<47::AID-MPO8>3.0.CO;2-N
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/abs/10.1002/1096-911X(200007)35:1%3C47::AID-MPO8%3E3.0.CO;2-N
dc.identifier.urihttp://hdl.handle.net/11452/21012
dc.identifier.volume35tr_TR
dc.identifier.wos000087946900008tr_TR
dc.indexed.pubmedPubmeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherWiley-Lissen_US
dc.relation.journalMedical and Pediatric Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectOncologyen_US
dc.subjectPediatricsen_US
dc.subjectHepatitis Ben_US
dc.subjectImmunizationen_US
dc.subjectChildhood canceren_US
dc.subjectVaccinationen_US
dc.subject.wosOncologyen_US
dc.subject.wosPediatricsen_US
dc.titleEfficacy of immunization against hepatitis B virus infection in children with canceren_US
dc.typeArticle

Files

License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science